Independent CE Satellite Symposium: From Sledgehammer to Selective: Transforming Cytotoxic Potency Through Targeted Treatments for Advanced or Metastatic Urothelial Cancer
Tuesday, October 27, 2020
4:00 PM – 5:15 PM EDT
Faculty:
Elizabeth R. Plimack, MD, MS Chief, Division of Genitourinary Medical Oncology Professor, Department of Hematology/Oncology Director, Genitourinary Clinical Research Fox Chase Cancer Center Temple University Health System Philadelphia, Pennsylvania
Susan K. Roethke, CRNP, MSN, ANP-BC, AOCNP Certified Registered Nurse Practitioner Genitourinary Medical Oncology Dept of Hematology/Oncology Fox Chase Cancer Center Temple University Health System Philadelphia, Pennsylvania
Brought to you by Integrity Continuing Education, an independent medical education company.
This activity supported by educational grants from Astellas, Merck Sharp & Dohme, and Seattle Genetics.
Articulate the mechanisms of action of targeted biopharmacologics and immune checkpoint inhibitors used in the treatment of UC
Outline efficacy and safety findings from key clinical trials of approved and investigational ICIs, ADCs, and FGFR inhibitors developed for the treatment of advanced or metastatic UC
Implement a patient-focused strategy for identifying, monitoring, and mitigating adverse events that can be caused by novel UC treatments
